Outlook Therapeutics names Kevin Lundquist as new CFO

Outlook Therapeutics, Inc. disclosed a leadership change in a Form 8-K dated August 23, 2026. Chief Financial Officer Lawrence A. Kenyon, who also served as Treasurer and Corporate Secretary and sat on the Board, mutually agreed with the company to cease those roles, effective September 1, 2026.¹

The Board appointed Kevin Lundquist as the company's Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer, effective the same transition date.¹

Lundquist brings prior finance leadership experience. He most recently served as CFO of CapsoVision Inc. from October 2024 to February 2026, where he led the company through its IPO, and before that was CFO of Abzena Biologics, Inc. from January 2022 to December 2023, and Vice President of Finance at Revance, Inc. from August 2020 to January 2022.¹ He holds an M.B.A. in International Finance from Utah State University and a B.S. in accounting and finance from the University of Utah.¹

Under his employment agreement, Lundquist will receive an initial annual base salary of $450,000, a target annual performance bonus of 50% of base salary, and participation in company benefit plans.¹ He also received an inducement stock option grant for 500,000 shares under Nasdaq Listing Rule 5635(c)(4).¹

Kenyon's exit was described as non-adversarial: his departure is not the result of any disagreement with the company on accounting, financial statements, internal controls, operations, policies or practices.¹ He will remain employed in a non-executive role through September 30, 2026, at his prior salary and benefits, and will step down from the Board by that date.¹ His separation terms include a lump sum equal to 12 months' base salary plus $20,000 and his full 2026 target bonus, full acceleration of stock option vesting, and up to 12 months of COBRA coverage.¹